ATLANTA, April 20, 2023 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. (“Avidity” or the “Company”) (NASDAQ: RNA) complied with federal securities laws. On March 30, 2023, Avidity provided an update on its product that is on a partial clinical hold for new patient enrollment by the FDA following a serious adverse event, stating that “discussions are ongoing” between the Company and the FDA and that “the Company continues to provide new data on AOC 1001 as it emerges from the MARINA Trial.” Following this disclosure, the price of the Company’s stock dropped.
If you purchased Avidity stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/avidity/ to discuss your legal rights.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
